Dynavax Technologies (NASDAQ:DVAX) Cut to “Sell” at The Goldman Sachs Group

The Goldman Sachs Group downgraded shares of Dynavax Technologies (NASDAQ:DVAX) from a neutral rating to a sell rating in a research report report published on Tuesday, Marketbeat Ratings reports. The Goldman Sachs Group currently has $12.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $15.00.

DVAX has been the subject of several other research reports. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. HC Wainwright raised their price objective on shares of Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, January 14th.

Dynavax Technologies Trading Down 3.8 %

NASDAQ DVAX opened at $12.70 on Tuesday. The firm has a 50 day simple moving average of $12.81 and a 200-day simple moving average of $11.91. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies has a one year low of $9.74 and a one year high of $13.89. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of 97.70 and a beta of 1.32.

Hedge Funds Weigh In On Dynavax Technologies

A number of institutional investors have recently modified their holdings of the business. Assenagon Asset Management S.A. purchased a new position in Dynavax Technologies in the 3rd quarter valued at $8,291,000. PDT Partners LLC purchased a new stake in shares of Dynavax Technologies in the 3rd quarter worth about $3,967,000. Nordea Investment Management AB boosted its position in shares of Dynavax Technologies by 42.7% in the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after buying an additional 232,690 shares in the last quarter. Mizuho Markets Americas LLC raised its stake in Dynavax Technologies by 17.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock valued at $15,369,000 after purchasing an additional 204,475 shares during the last quarter. Finally, Barclays PLC raised its stake in Dynavax Technologies by 137.4% in the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock valued at $3,371,000 after purchasing an additional 175,118 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.